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between endothelial function (as judged by elevated EPMP 
levels, with no change in PMPs) and renal function. Other 
markers of prothombotic state or cellular activation (PMP, 
P-selectin	and	E-selectin	levels)	were	not	significantly	dif-
ferent across the various degree of renal dysfunction. Renal 
function must be addressed when measuring EPMP levels.
Keywords	 Atrial	fibrillation	·	Chronic	renal	disease	·	
Microparticles	·	Soluble	P	selectin	·	Soluble	E	selectin
Introduction
Non-valvular	 atrial	 fibrillation	 (AF)	 is	 associated	with	 an	
elevated risk of ischaemic stroke and systemic thromboem-
bolism [1, 2]. This risk is further increased by concurrent 
diagnosis of chronic kidney disease (CKD) or end-stage 
renal disease (ESRD) and results in a worse clinical out-
come in terms of cardiovascular disease [3–5]. The pre-
cise	mechanism(s)	 underlying	 the	 worse	 outcomes	 in	AF	
patients with CKD and ESRD are incompletely understood 
and so require further investigation. One such aspect is cir-
culating microparticles, known to be increased in dialysis 
dependent ESRD [6]. These microparticles are heterog-
enous vesicles, derived from cellular membrane where the 
parent cells have undergone necrosis, injury, apoptosis or 
activation [7, 8]. Depending on the nature of their parent 
cells (such as leukocytes, platelets and endothelial cells), 
different microparticles subsets possess a unique composi-
tion and content, which vary in their thrombotic potentials 
[9–11 ]. Thus, different microparticles subsets can not only 
mark	pathology	of	their	parent	cells,	but	may	also	influence	
coagulation by directly facilitating formation of coagula-
tion complexes or via modulation of tissue factor dependent 
pat ways [12 , 13].
Abstract	 Atrial	fibrillation	(AF)	and	chronic	kidney	dis-
ease are closely related, and any associated risk of stroke
and	 thromboembolism	 due	 to	AF	 is	 increased	 by	 concur-
rent renal dysfunction. The m chanism(s) for th s include 
abnormalities in platelets and endothelial cells. We hypoth-
esized relationships between levels of circulating platelet 
microparticles	(PMPs,	defined	by	CD42b),	soluble	P	selec-
tin	 (both	 reflecting	 platelet	 activation),	 soluble	 E-selectin	
(reflecting	 endothelial	 activation)	 and	 endothelial/platelet	
microparticles	 (EPMPs,	 defined	 by	 CD31)	 with	 progres-
sive renal dysfunction. Blood samples were obtained from 
160	anticoagulated	AF	patients.	Microparticles	were	mea-
sured	 by	 flow	 cytometry,	 soluble	 E	 and	 P	 selectin	 levels	
by ELISA. Renal function was determined by estim ted 
glomerular	 filtration	 rate	 (eGFR).	 EPMP	 levels	 demon-
strated	 a	 linear	 increased	 trend	 across	 quartiles	 of	 eGFR	
(p = 0.034) and CKD stage (p < 0.001), and correlated w th 
eGFR	 and	 serum	 creatinine	 (p	< 0.01). PMPs, P-selec-
tin	 and	 E-selectin	 levels	 were	 not	 significantly	 different	
across	 groupings	 of	 renal	 dysfunction,	 and	 no	 significant	
correlations	with	eGFR	were	evident	(p	= 0.186, p= 0.561, 
p = 0.746 respectively). Stepwise multivariable regression 
analysis demonstrated that worsening renal fun tion was an 
independent predictor of EPMP levels (p < 0.001). In wel -
anticoagulated	AF	 patients,	 there	 is	 potential	 relationship	
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Laboratory methods
Blood samples were collected from a large antecubital vein 
using a 21-gauge needle directly into Vacutainer® tub s 
(Becton Dickinson, UK) containing 0.5 ml 3.2 % sodium 
citrate.	 For	 microparticle	 detection,	 platelet-poor	 plasma	
(PPP) was obtained after 15 min centrifugation of citrated 
blood at 2800g and further centrifugation of PPP at 13,000g 
for 2 min to remove residual cellular fragments to obtain 
platelet-free	plasma	(PFP)	as	per	ISTH	guidelines	[20]. Ali-
quots of the plasmas were frozen at −70 °C for subsequent 
batch analysis and so had undergone a single-freeze thaw 
cycle.
PFP	was	 initially	 incubated	 separately	 for	 30	min	with	
0.5	μg	of	biotinylated	anti-human	CD42b	antibody	(Abcam,	
Cambridge, UK) for platelet-derived microparticles (PMP), 
or	 0.5	 μg	 of	 biotinylated	 anti-human	 antibody	 to	 CD31	
(PECAM, present on both platelets and endothelial cells) 
(Abcam, Cambridge, UK) for mixed endothelial-derived 
microparticles (EPMPs). This was followed by a second incu-
bation	with	0.25	μg	of	Streptavidin-Alexa	Fluor-647	nm-R-
Phycoerythrin conjugate (Life Technology, Paisley, UK) for 
30	min	and	then	diluted	with	990	μl	filtered	PBS	(final	dilu-
tion 1:100). MP analysis was promptly performed using the 
Apogee	A50	flow	cytometer	(Apogee	Flow	Systems,	High	
Wycombe, UK). Polystyrene beads of 110, 200, 500 nm and 
1	μm	diameter	(Apogee	Flow	Systems)	were	used	to	set	up	
the	MP-size	gate	and	small-size	MP	defined	as	events	with	
size between 110 and 500 nm. Detailed instruction regard-
ing gating selection has previously been described [21]. 
For	 enzyme-linked	 immunosorbent	 assay	 (ELISA)	 blood	
samples were centrifuged within 30 min from collection at 
1500g for 20 min at 4 °C. The resultant plasma was then col-
lected and stored at −70 °C until later batch processing by 
ELISA to measure soluble E-selectin and soluble P-selectin 
(R&D Systems, Abingdon, UK).
Statistical analysis
Continuously variable data are expressed as mean and stan-
dard deviation (SD) or median and interquartile range (IQR) 
dependent on distribution. To demonstrate a step change in 
research	indices,	data	were	grouped	by	quartile	of	eGFR	and	
also by the clinical tool of CKD stage, that being Stage 1 
(eGFR	≥90 ml/min/1.73 m2),	Stage	2	(eGFR	60–89),	Stage	
3	(eGFR	30–59)	and	Stage	4/5	combined	(eGFR	≤29) [22]. 
When the groups are ordered it is not reasonable to com-
pared each pair of groups with each other (as in an analy-
sis of variance of groups that are independent), but instead 
consideration should be given whether there is a linear trend 
across the four groups. This was sought according to meth-
ods described by Altman [23].	However,	as	 he	eGFR	has	a	
natural continuous variation, correlations were also sought 
Although microparticles levels are increased in ESRD 
and are linked to increased cardiovascular mortality [6, 14], 
a	 contradictory	 relationship	 exists	 between	AF	 and	 levels	
of circulating microparticles [15, 16]. A potential relation-
ship between worsening degr es of non-dialysis dependent 
renal	dysfunction	and	microparticles	amongst	AF	patients,	
as well as the subsequent effect on levels of va ious mic-
roparticle subsets, has yet t  be investigated.
In this study, we hypothesised that, in patients at risk of 
a	thrombotic	events	(that	is,	with	AF)	levels	of	platelet	mic-
roparticles and/or endothelial/platelet microparticles would 
be	 associated	 inversely	 with	 renal	 function,	 as	 defined	 by	
the	estimated	glomerular	filtration	rate.	To	provide	perspec-
tive for the microparticle aspect, we l o measured levels of 
two plasma markers of platelet and ndothelial biology, these 
being soluble P selectin and soluble E selectin r spectively,
both known to be abnormal in cardiovascular disease [17, 18].
Patients and methods
Subjects
All	160	subjects	with	non-valvular	AF	were	recruited	from	
routine out-patient clinics, and all had been taking oral 
anticoagulation (warfarin) for at least 12 weeks. Dos -
adjustment for warfarin was don  in specialise  cientist-
led anticoagulation clinics, achieving a stabl  in ernational 
normalised ratio (INR) between two and three. INR was 
again determined on the day of testing to assess effective 
anticoagulation.
Exclusion criteria were age <18 years, diagnosis of valvu-
lar	AF	(severe	rheumatic	stenosis,	metallic	prosthetic	valve,	
mitral/tricuspid ring repair), active or cen (<12 mon hs) 
malignancy, active immunological di ease, chronic liver 
disease,	recent	or	chronic	infections,	chronic	inflammatory	
disease, connective tissue disease, recent stroke/acute coro-
nary syndrome (within 2 months), active bleeding, recent 
arterial/venous thrombosis or recent surgery, known haemo-
philia	or	 thrombophilia	 (such	as	Factor	V	Leiden,	Protein	
C/S/anti-thrombin	deficiency,	anti-phospholipid	syndrome),	
use of an anti-platelet agent oth r than aspirin, and use of an 
oral anticoagulant other than warf rin. Standard clinical and 
demographic data were obtained.
A routine blood test was taken for to assess for renal 
function (urea, creatinine and electrolytes), with subsequent 
calculation	 of	 estimated	 glomerular	 filtration	 rate	 (eGFR)	
[19].	To	aid	clarity,	patients	with	CKD	stages	four	and	five	
were merged into a single group [20]. In acc rdance wi  
the Declaration of Helsinki, the p oject was approved by 
the Local Research Ethics Committee and written informed 
consent was obtained from each subject. Data were ano-
nymised prior to statistical analysis.
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EPMP levels increased sequentially across the quartiles 
of	worsening	renal	function	as	defined	by	eGFR,	but	there	
were no differences in PMP, soluble P-selectin, or E-selec-
tin levels (Table 2). The trend in EPMP across CKD stages 
1–4/5 of 8.62 (3.94–18.23), 6.12 (1.62–12.78), 9.21 (1.82–
23.17) and 21.05 (3.1-46.47) × 103/µl respectively, although 
not	 completely	 linear,	 was	 nonetheless	 highly	 significant	
(p < 0.001).
There	 was	 a	 significant	 negative	 correlation	 between	
eGFR	and	EPMP,	and	a	positive	correlation	between	serum	
creatinine and EPMP (r = 0.209, p = 0.008) (Table 3). 
There	were	no	significant	correlations	between	eGFR	and	
PMP, soluble P-selectin or soluble E-selectin levels. Using 
stepwise regression analysis of indices in Table 1 with 
p < 0.05, the only independent predictor EPMP was the 
eGFR	(p	< 0.001). Other demographic factors and comor-
bidities	 did	 not	 have	 any	 significant	 impact	 on	 EPMP	
levels.
using Spearman’s method. Categorical indic s were anal-
ysed by the Chi squared test. Stepwise regr ssion analyses 
were	 performed	 to	 determine	 independent	 influences	 on	
research indices. All analyses w r  performed on Minitab 
17, and p <	0.05	was	considered	as	significant.
Results
Clinical	 and	 demographic	 details	 of	 the	 160	AF	 patients	
sorted	by	quartile	of	eGFR	are	shown	in	Table	1. There were 
no	significant	differences	in	INR,	gender,	most	comorbidi-
ties, race (black vs. non-black), systolic blood pressure, nic
otine use or concurrent antiplatelet use. A  expected, there 
was worsening renal function with increasing CKD stage, 
age and creatinine level, but diastolic blood pressure and 
BMI were lowest in those with worse ren l function. Diabe-
tes was linked to worsening renal function.
eGFR P for 
linear 
trendQuartile 1: best 
renal function
Quartile 2Quartile 3Quartile 4:
worst renal 
function
eGFR	(ml/ 
min/1.73)
87 (5) 70 (3) 56 (6) 30 (7) <0.001
Age (years) 68 (12) 74.5 (8) 74 (7) 80 (8) <0.001
Sex (m/f) 24/16 21/19 22/18 21/19 0.895
Race (non-black/
black)
37/3 39/1 33/7 35/5 0.135
Weight (kg) 92 (24) 87 (22) 83.5 (15) 76 (21) <0.001
Creatinine (µmol/l)70 (13) 85 (14) 109 (25) 166 (60) <0.001
INR 2.6 (0.8) 2.6 (0.7) 2.5 (0.8) 2.4 (0.6) 0.086
SBP (mmHg) 132 (18) 135 (17) 126 (24) 129 (18) 0.096
DBP (mmHg) 76 (13) 75 (12) 72 (13) 69 (9) 0.002
BMI (kg/m2) 30.3 (6.3) 31.0 (5.6) 29.5 (4.6) 28.1 (6.8) 0.027
Co-morbidities (yes/no)
Ischaemic heart 
disease
12/28 15/25 16/24 23/17 0.082
Type 2 diabetes 
mellitus
14/26 11/29 17/23 24/16 0.022
Hypertension33/7 34/6 33/7 35/5 0.914
Heart failure12/28 12/28 15/25 21/19 0.124
COPD 9/31 4/36 5/35 9/31 0.296
Concurrent 
antiplatelet
2/38 2/38 4/36 4/36 0.696
Current smoker2/38 1/39 1/39 2/38 0.875
CKD stage  
1/2/3/4 (n)
23/17/0/0 0/40/0/0 0/12/28/0 0/0/17/23 <0.001
Median (IQR)  
CKD stage
1 (1–2) 2 (2–2) 3 (2–3) 4 (3–4) <0.001
Data mean (standard deviation), number of subjects, or median and inter-quartile range (CKD stage)
eGFR	estimated	glomerular	filtration	rate,	INR international normalised ratio, SBP systolic blood pres-
sure, DBP diastolic blood pressure, BMI body mass index
Table 1 Clinical and demo-
graphic data
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we presume the majority of those of Chen et al. and Lu et al. 
were	from	the	Far	East),	and	differences	in	ELISA	reagents.
As EPMPs may arise from endothelial cells and plate-
lets in response to damage/activation, increased levels may 
reflect	 pathology	 of	 either	 or	 both	 parent	 cells.	We	 used	
CD31, also known as PECAM, is found on the surface of 
both platelets and endothelial cells [29–32]. However, the 
failure of ‘pure’ PMPs to associate with any renal func-
tion index provide support for the hypothesis that EPMPs 
are	more	 likely	 to	 reflect	 endothelial	 pathology	 [33]. The 
presence of greater vascular and endothelial injury associ-
ated with (or as a result of) progressive renal dysfunction 
will cause alteration to EMP levels. Hence, this study also 
extends previous work by demonstrating a progressive, 
step-wise, increase in EPMP levels among those with wors-
ening degrees of renal failure. Nevertheless, elevated CD31/
annexin-V EPMP levels are present in acute coronary syn-
dromes, may be a surrogate of cellular injury due to car-
diovascular risk diseases, and correlate with cardiovascular 
outcomes [34–36], but this can be accounted for in our study 
by the similar comorbidities.
Our	 study	 demonstrates	 the	 lack	 of	 significant	 change	
in PMP levels in relation with worsening renal function 
among	AF	patients.	Previous	studies	 [15, 37] have shown 
that PMP levels are affected less by arrhythmia and more to 
underlying cardiovascular diseases. Lu et al. [28] also found 
that	CD41-defined	PMPs	and	soluble	P	selectin	were	pro-
gressively lower in those with the worse CKD, in contrast 
to our data which found no such relationship. The lack of 
alterations in soluble P-selectin and E-selectin levels across 
subjects with worsening renal function suggests that these 
biomarkers of platelet and endothelial cell activation may 
be less affected by renal (dys)function.
Limitations of our study include lack of data regarding 
the potential roles of other microparticles besides PMP 
and	 EPMP,	 such	 as	 ‘pure’	 endothelial	 (e.g.	 as	 defined	 by	
CD62E, CD144, CD146, etc. [8, 26, 38]), or leukocyte sub-
sets.	Furthermore,	all	patients	were	taking	warfarin,	so	that	
extrapolation	of	non-AF	and/or	non-anticoagulated	groups	
Discussion
Renal function is an emerging additional isk factor for 
cardiovascular disease [24].	As	AF	 and	 CKD	 are	 closely	
linked, there is a strong need to identify pote tial markers 
that enable assessment of the declin  of renal function and 
alteration(s) of thrombotic potential [1–5]. We demonstrate 
that	among	AF	patients	receiving	oral	anticoagulation,	pro-
gressive worsening of renal function is associated with a 
linear trend of increasing levels of EPMP. Reduced d astolic
blood pressure in patients wi  greatest renal dysfunction 
may be due to the higher proportion of p tient with isch-
aemic heart disease and the likelihood that they will be more 
intensively treated. Similarly, he increasing frequency of 
diabetes across the groups is very ik y to be due to diabetic 
nephropathy. Nevertheless, neither of these factors wer  
selected on multivariate an lysis and rena  function emerged 
as the only independent determinant of EPMP levels.
Our	 current	 finding	 confirms	 previous	 studies	 finding	
increased microparticles in r n l dysfu ction/failur  [6, 25, 
26]. However, our data contrasts with the lack of positive 
findings	in	other	studies,	possible	because	of	the	use	of	dif-
ferent antibodies, such as to CD144, CD146 and CD41 [26], 
annexin-V [27] and/or to CD69E [28],	and	 so	defining	dif-
ferent species of MP [8], in demographic and co-morbidities 
(the	approximate	mean	age	of	the	patients	of	Fauvre	et	al.	[26] 
is 59 years, of Lu et al. [28] is 47 years, of Chen et a . [27] i  
is 70 years, whilst in our patients it s 74 years), racial back-
ground (90 % of our patients were of Eur pean desce  whilst 
eGFR P for 
linear 
trendQuartile 1Quartile 2Quartile 3Quartile 4
PMPs events/µl281 (134–1348) 2123 (324–4079) 1476 (82–5041) 209 (29–2043) 0.897
EPMPs 
events/103/µl
5.18 (0.74–12.35)6.52 (4.22–11.67)6.09 (0.41–24.45)21.05 
(6.43–29.71)
0.034
Soluble P selectin 
(ng/ml)
9.1 (7.3–11.0) 9.0 (7.6–10.4) 9.1 (7.2–11.4) 8.3 (6.2–10.8)0.368
Soluble E selectin 
(ng/ml)
39 (29–105) 39 (27–74) 43 (29–63) 39 (26–45) 0.930
Data presented as median and IQR
PMPs platelet microparticles, EPMPs endo he ial/platelet microparticles
Table 3	Spearman	 correlations	 of	 the	 eGFR	 with	 microparticles,	
P-selectin and E-selectin levels
rs p
Platelet microparticles0.095 0.234
Endothelial/platelet microparticles−0.319 <0.001
Soluble P selectin 0.086 0.279
Soluble E selectin 0.133 0.094
rs	Spearman’s	correlation	coefficient
Table 2 Microparticles, soluble 
P-selectin and soluble E-selectin 
levels according to quartiles of
eGFR
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may	 be	 difficult,	 and	 without	 a	 platelet	 count	 we	 cannot	
relate this index to PMPs or soluble P selectin. However, we 
have previously been unable to link soluble P selectin with 
platelet count [39, 40].	 Further	studies	should	be	performed	
to investigate their potential invol ement in the relationship 
of	progressive	renal	dysfunction	and	AF.
In	 conclusion,	 among	well-anticoagulated	AF	 patients,	
there is relationship between endoth lial function (as ju ged 
by EPMPs) and renal function. Other markers of prothom-
botic state or cellular activation, such as PMP, P-selectin 
and	E-selectin	levels	were	not	significantly	different	across	
the various degree of renal dysfunction.
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